Premier Perspectives The blog for insider insights in clinical development Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseLife at Premier By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Clinical ResearchPhase 1 - Phase 4 Six Insights To Treating Fibromyalgia By Scott Millard July 14, 2017 Consulting Rushing Site Selection in Fibromyalgia Trials, Not a Great Idea By Scott Millard July 7, 2017 Clinical ResearchPhase 1 - Phase 4 Fighting the Placebo Effect in Fibromyalgia Drug Trials By Scott Millard June 23, 2017 Consulting Distinctive Characteristics of Fibromyalgia Patients By Scott Millard June 12, 2017 Clinical ResearchPhase 1 - Phase 4 In Treating Fibromyalgia, Goal Is Overall Benefit — Not Just Less Pain By Scott Millard May 31, 2017 Clinical ResearchPhase 1 - Phase 4 10 Best Practice Recommendations for Short-Duration Acute Pain Management Trials By Scott Millard April 28, 2017 Previous 1 …3 4 5 6 Next × ALSO OF INTERESTPremier Voices #3: The Placebo Problem Part 1...The 5 Components of an Effective Target Product ProfileOperationalizing Fibromyalgia Trials
